Skip to main content
Clinical Trials/JPRN-UMIN000051549
JPRN-UMIN000051549
Recruiting
N/A

Prospective interventional clinical study to evaluate the efficacy and safety of atezolizumab plus bevacizumab in combination with carbon ion radiotherapy for unresectable hepatocellular carcinoma - Prospective interventional clinical study to evaluate the efficacy and safety of atezolizumab plus bevacizumab in combination with carbon ion radiotherapy for unresectable hepatocellular carcinoma

Yamagata University0 sites20 target enrollmentJuly 7, 2023

Overview

Phase
N/A
Intervention
Not specified
Conditions
hepatocellular carcinoma
Sponsor
Yamagata University
Enrollment
20
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 7, 2023
End Date
September 30, 2027
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Patients with untreated or poorly treated esophageal aneurysms and/or gastric varices with or judged to be at high risk for bleeding. Patients who have undergone esophagogastroduodenoscopy (EGD) prior to enrollment, have been examined and treated for varices, and have been determined to be at low risk for bleeding will be eligible for enrollment. (EGD will not be required if performed within 6 months prior to starting atezolizumab/bevacizumab combination therapy.) Patients who are deemed inappropriate by the principal investigator or study investigators to participate in this study.

Outcomes

Primary Outcomes

Not specified

Similar Trials